Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the

newsfileApr 2 07:30 ET

FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients

Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age groupToronto, Ontario and Chicago, Ill

newsfileMar 26 07:53 ET

Medexus Pharmaceuticals Inc Price Target Cut to C$2.35/Share From C$2.85 by Stifel Nicolaus

Medexus Pharmaceuticals Inc Price Target Cut to C$2.35/Share From C$2.85 by Stifel Nicolaus

Dow JonesFeb 22 11:33 ET

Medexus Pharmaceuticals Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next

Yahoo FinanceFeb 10 07:24 ET

Medexus Pharmaceuticals Maintained at Speculative Buy at Stifel GMP After Fiscal Q3 Miss; Price Target Cut to C$2.85

Stifel GMP on Friday reiterated its speculative-buy rating on the shares of Medexus Pharmaceuticals (MDP.TO) after lowering its price target to C$2.85 from C$3.50 after the company reported weaker tha

MT NewswiresFeb 9 11:37 ET

Medexus Pharmaceuticals Announces Fiscal Q3 2024 Results

Medexus Pharmaceuticals Inc. (MDP.TO) overnight Wednesday reported its Q3 2024 results. The company announced adjusted net loss of $0.53 million, compared with adjusted loss of $0.9 million, last year

MT NewswiresFeb 8 09:13 ET